|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
ATE538794T1
(de)
*
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
WO2000042012A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
NZ528846A
(en)
*
|
1999-03-12 |
2005-05-27 |
Boehringer Ingelheim Pharma |
Compounds useful as anti-inflammatory agents
|
|
EP1466906A1
(en)
*
|
1999-03-12 |
2004-10-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
ATE312823T1
(de)
*
|
1999-07-09 |
2005-12-15 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
|
WO2001036403A1
(en)
*
|
1999-11-16 |
2001-05-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Urea derivatives as anti-inflammatory agents
|
|
US6635767B2
(en)
*
|
2000-05-23 |
2003-10-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US6822093B2
(en)
|
2000-05-23 |
2004-11-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1362037A1
(en)
|
2001-02-15 |
2003-11-19 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
|
|
WO2002081420A1
(en)
*
|
2001-04-03 |
2002-10-17 |
Eisai Co., Ltd. |
Cyclooctanone derivative and cyclodecanone derivative, and use thereof
|
|
MXPA03009361A
(es)
*
|
2001-04-13 |
2004-01-29 |
Boehringer Ingelheim Pharma |
Compuestos de urea utilies como agentes anti-inflamatorios.
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
WO2002092576A1
(en)
*
|
2001-05-16 |
2002-11-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Diarylurea derivatives useful as anti-inflammatory agents
|
|
IL158941A0
(en)
|
2001-05-22 |
2004-05-12 |
Neurogen Corp |
Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
|
|
EP1935885A3
(en)
*
|
2001-05-22 |
2008-10-15 |
Neurogen Corporation |
Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
AU2002310156A1
(en)
|
2001-06-05 |
2002-12-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
|
US8329924B2
(en)
*
|
2001-06-11 |
2012-12-11 |
Vertex Pharmaceuticals (Canada) Incorporated |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
|
CN101624391A
(zh)
*
|
2001-06-11 |
2010-01-13 |
病毒化学医药公司 |
用作黄病毒感染抗病毒剂的噻吩衍生物
|
|
JP2004537536A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
|
|
EP1401411A2
(en)
*
|
2001-06-29 |
2004-03-31 |
AB Science |
Use of tyrosine kinase inhibitors for treating bone loss
|
|
ES2266553T3
(es)
|
2001-06-29 |
2007-03-01 |
Ab Science |
Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
|
|
JP2005500041A
(ja)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
|
|
DE60215648T2
(de)
|
2001-06-29 |
2007-08-23 |
Ab Science |
Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
EP1414800B1
(en)
*
|
2001-07-11 |
2004-12-29 |
Boehringer Ingelheim Pharmaceuticals Inc. |
A novel synthesis for heteroarylamine compounds
|
|
EP1709965A3
(en)
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
|
JP2004536845A
(ja)
*
|
2001-07-11 |
2004-12-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介疾患の治療方法
|
|
PE20030417A1
(es)
|
2001-09-13 |
2003-08-06 |
Smithkline Beecham Plc |
Derivados de urea como antagonistas del receptor vainilloide
|
|
JP2005503400A
(ja)
*
|
2001-09-13 |
2005-02-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介病の治療方法
|
|
EP1438048A1
(en)
*
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
|
US20080108672A1
(en)
*
|
2002-01-11 |
2008-05-08 |
Bernd Riedl |
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
|
MXPA04007830A
(es)
|
2002-02-11 |
2005-07-01 |
Bayer Pharmaceuticals Corp |
Arilureas como inhibidores de cinasa.
|
|
ATE386030T1
(de)
|
2002-02-25 |
2008-03-15 |
Boehringer Ingelheim Pharma |
1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
|
|
AU2003224025A1
(en)
*
|
2002-04-05 |
2003-10-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
p38 kinase inhibitors for treating mucus hypersecretion
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
ES2343787T3
(es)
*
|
2002-04-11 |
2010-08-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Derivados de amidas heterociclicas de utilizacion como inhibidores de citoquina.
|
|
US20030236287A1
(en)
*
|
2002-05-03 |
2003-12-25 |
Piotrowski David W. |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
|
CN1309703C
(zh)
*
|
2002-06-19 |
2007-04-11 |
纽若泰克有限公司 |
四氟苄基衍生物及含有其成分的用于治疗和预防中枢神经系统的急慢性神经变性疾病的药物组合物
|
|
US20040044020A1
(en)
*
|
2002-07-09 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
|
|
DE60310730T2
(de)
*
|
2002-07-09 |
2007-05-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
|
CA2494824A1
(en)
|
2002-08-08 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
|
US7232828B2
(en)
*
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
|
US20040110755A1
(en)
*
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
|
CA2496445A1
(en)
*
|
2002-08-14 |
2004-02-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
|
|
US7179836B2
(en)
*
|
2002-09-20 |
2007-02-20 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
EP1565477A1
(en)
*
|
2002-11-22 |
2005-08-24 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Preparation of aryl intermediate compounds using trialkylmagnesate reagents
|
|
US7402608B2
(en)
*
|
2002-12-10 |
2008-07-22 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
CA2517517C
(en)
*
|
2003-03-03 |
2012-12-18 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
US7135575B2
(en)
*
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
JP3910627B2
(ja)
|
2003-03-12 |
2007-04-25 |
ファイザー・プロダクツ・インク |
ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体
|
|
GB2400101A
(en)
*
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
|
WO2004101529A1
(ja)
*
|
2003-05-19 |
2004-11-25 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその医薬用途
|
|
WO2004113274A2
(en)
*
|
2003-05-20 |
2004-12-29 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
|
EA010485B1
(ru)
*
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
CA2536293A1
(en)
*
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
CA2552087C
(en)
*
|
2004-01-30 |
2011-01-25 |
Euro-Celtique S.A. |
Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
|
|
CN101010315A
(zh)
*
|
2004-04-30 |
2007-08-01 |
拜耳制药公司 |
用于治疗癌症的取代的吡唑基脲衍生物
|
|
US7550499B2
(en)
*
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
PT1761520E
(pt)
|
2004-06-23 |
2008-09-15 |
Lilly Co Eli |
Inibidores de quinase
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
EP1807085B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
CA2580857A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
CA2580762A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
JP2008523071A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ， インコーポレイテッド |
Ｍａｐキナーゼの尿素インヒビター
|
|
EP1824843A2
(en)
*
|
2004-12-07 |
2007-08-29 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
EP1954696B1
(en)
*
|
2005-01-19 |
2011-02-23 |
Bristol-Myers Squibb Company |
2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
|
|
BRPI0610283A2
(pt)
*
|
2005-05-13 |
2010-10-19 |
Virochem Pharma Inc |
composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
|
|
NZ562772A
(en)
*
|
2005-05-24 |
2010-01-29 |
Serono Lab |
Tricyclic spiro derivatives as CRTH2 modulators
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
DE602006020871D1
(de)
|
2005-06-27 |
2011-05-05 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
|
|
EP1899299B1
(en)
*
|
2005-06-27 |
2010-10-20 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
WO2007002634A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
AR056867A1
(es)
*
|
2005-06-27 |
2007-10-31 |
Bristol Myers Squibb Co |
Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
|
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
US20070049565A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Neurotech Pharmaceuticals Co., Ltd. |
Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
|
|
US20070298129A1
(en)
*
|
2005-08-24 |
2007-12-27 |
Neurotech Pharmaceuticals Co., Ltd. |
Compounds and compositions for treating neuronal death or neurological dysfunction
|
|
WO2007044490A2
(en)
*
|
2005-10-06 |
2007-04-19 |
Boehringer Ingelheim International Gmbh |
Process for making heteroaryl amine intermediate compounds
|
|
CA2635888A1
(en)
*
|
2006-01-04 |
2007-07-19 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
KR101357465B1
(ko)
*
|
2006-01-31 |
2014-02-03 |
어레이 바이오파마 인크. |
키나제 억제제 및 그의 사용 방법
|
|
WO2007109434A1
(en)
*
|
2006-03-17 |
2007-09-27 |
Boehringer Ingelheim International Gmbh |
Besylate salt form of 1- (5-tert-butyl-2-p-t0lyl-2h-pyraz0l-3-yl) -3- (4- (6- (morpholin-4-yl-methyl) -pyrid in- 3 -yl) -naphthalen- 1-yl) -urea and polymorphs thereof
|
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
CA2670260A1
(en)
|
2006-11-15 |
2008-05-22 |
Virochem Pharma Inc. |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
KR100852962B1
(ko)
*
|
2007-11-12 |
2008-08-20 |
주식회사 뉴로테크 |
2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
|
|
AR069650A1
(es)
*
|
2007-12-14 |
2010-02-10 |
Actelion Pharmaceuticals Ltd |
Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
|
|
EP3613743B1
(en)
|
2008-01-04 |
2022-03-16 |
Intellikine, LLC |
Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CA2710462C
(en)
*
|
2008-02-05 |
2015-11-24 |
F. Hoffmann-La Roche Ag |
Pyridinones and pyridazinones
|
|
RU2496778C2
(ru)
*
|
2009-03-09 |
2013-10-27 |
Тайхо Фармасьютикал Ко., Лтд. |
Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
PT2544679T
(pt)
|
2010-03-12 |
2019-07-11 |
Omeros Corp |
Inibidores de pde-10 e composições e métodos relacionados
|
|
EP2556068B1
(en)
|
2010-04-08 |
2019-01-23 |
Respivert Limited |
P38 map kinase inhibitors
|
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
|
TWI674262B
(zh)
|
2011-01-10 |
2019-10-11 |
美商英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
|
US10245255B2
(en)
*
|
2011-02-14 |
2019-04-02 |
The Regents Of The University Of Michigan |
Compositions and methods for the treatment of obesity and related disorders
|
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
|
US8809372B2
(en)
|
2011-09-30 |
2014-08-19 |
Asana Biosciences, Llc |
Pyridine derivatives
|
|
US8476303B2
(en)
*
|
2011-10-31 |
2013-07-02 |
Florida A&M University Board of Trustees |
N-aminopyrrolylmethyltetrahydropyridines as anti-cancer agents
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
EP2890701B1
(en)
|
2012-08-29 |
2017-03-29 |
Respivert Limited |
Kinase inhibitors
|
|
US20150210722A1
(en)
|
2012-08-29 |
2015-07-30 |
Respivert Limited |
Kinase inhibitors
|
|
US20150225373A1
(en)
|
2012-08-29 |
2015-08-13 |
Respivert Limited |
Kinase inhibitors
|
|
EP2914296B2
(en)
|
2012-11-01 |
2021-09-29 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
KR102283876B1
(ko)
|
2013-04-02 |
2021-07-29 |
옥슬러 액퀴지션즈 리미티드 |
키나제 저해제로서 유용한 우레아 유도체
|
|
US9771353B2
(en)
|
2013-04-02 |
2017-09-26 |
Topivert Pharma Limited |
Kinase inhibitors based upon N-alkyl pyrazoles
|
|
WO2014179734A1
(en)
|
2013-05-02 |
2014-11-06 |
The Regents Of The University Of Michigan |
Deuterated amlexanox
|
|
EP3083604A1
(en)
|
2013-12-20 |
2016-10-26 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
NZ630803A
(en)
|
2014-04-28 |
2016-03-31 |
Omeros Corp |
Optically active pde10 inhibitor
|
|
NZ716494A
(en)
|
2014-04-28 |
2017-07-28 |
Omeros Corp |
Processes and intermediates for the preparation of a pde10 inhibitor
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
|
US9879002B2
(en)
|
2015-04-24 |
2018-01-30 |
Omeros Corporation |
PDE10 inhibitors and related compositions and methods
|
|
US9920045B2
(en)
|
2015-11-04 |
2018-03-20 |
Omeros Corporation |
Solid state forms of a PDE10 inhibitor
|
|
US10214536B2
(en)
|
2016-01-29 |
2019-02-26 |
The Regents Of The University Of Michigan |
Amlexanox analogs
|
|
CA3015978A1
(en)
|
2016-04-06 |
2017-10-12 |
Topivert Pharma Limited |
Kinase inhibitors
|
|
RU2754507C2
(ru)
|
2016-06-24 |
2021-09-02 |
Инфинити Фармасьютикалз, Инк. |
Комбинированная терапия
|
|
CN106632403B
(zh)
*
|
2017-01-23 |
2018-09-11 |
牡丹江医学院 |
一种手术用止痛消炎药及其制备方法
|
|
US10364245B2
(en)
|
2017-06-07 |
2019-07-30 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
|
EP3728228A1
(en)
|
2017-12-22 |
2020-10-28 |
Ravenna Pharmaceuticals, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
KR102708177B1
(ko)
|
2018-01-31 |
2024-09-23 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양의 치료를 위한 병용 요법
|
|
EP3938363A1
(en)
|
2019-03-11 |
2022-01-19 |
Teva Pharmaceuticals International GmbH |
Solid state forms of ripretinib
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
LT4013412T
(lt)
|
2019-08-12 |
2026-03-25 |
Deciphera Pharmaceuticals, Llc |
Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
|
|
PT4013412T
(pt)
|
2019-08-12 |
2026-03-18 |
Deciphera Pharmaceuticals Llc |
Ripretinib para o tratamento de tumores estromais gastrointestinais
|
|
HRP20231699T1
(hr)
|
2019-12-30 |
2024-05-10 |
Deciphera Pharmaceuticals, Llc |
Formulacije inhibitora amorfne kinaze i postupci njihove primjene
|
|
CN115243681B
(zh)
|
2019-12-30 |
2024-08-16 |
德西费拉制药有限责任公司 |
1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
|
|
AU2021232072A1
(en)
*
|
2020-03-05 |
2022-10-20 |
Centessa Pharmaceuticals (Uk) Limited |
STAT inhibitory compounds and compositions
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
CN116987041A
(zh)
*
|
2023-08-02 |
2023-11-03 |
河北科技大学 |
一种转移氢化法制备5-(2-氨基-4-氯苯基)四氮唑的方法
|